BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

• click to rate

  Posted by Two Blokes Jun 4 - Filed in Stock - 2 views
  
  Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.